BioHarvest Sciences to Unveil Q2 2026 Financial Results on August 11, 2026

Earnings Call Information and Registration Instructions

BioHarvest has scheduled its Q2 2026 earnings presentation for Tuesday, August 11, 2026, with financial results released before market open. The live webcast and conference call will begin at 8:00 AM Eastern Time on the same day. Attendees wishing to participate in the live session are encouraged to register via the webcast link at least 10 minutes before the call to ensure seamless access.

The direct webcast link for the event is: https://events.q4inc.com/attendee/553034064. This will enable shareholders, investors, and interested parties to listen to management’s presentation and engage in the Q&A session. For those unable to attend live, a recording will be posted in the Investor Relations section under Events & Presentations on BioHarvest’s website.

CEO Rakib’s Strategic Outlook and Company Update

CEO Zaki Rakib, approaching his first 100 days in office at the time of the earnings call, expressed anticipation to present Q2 results and provide insights into the company’s 2026 strategy and growth roadmap. His remarks highlight management’s dedication to transparency with shareholders and the investment community regarding operational progress and future priorities.

Rakib’s invitation to shareholders and investors to join the August 11 call indicates the company plans to use the earnings presentation to outline its strategic direction, review progress, and discuss upcoming opportunities. This suggests the call will extend beyond financial results to include operational updates and strategy clarification during this leadership transition period.

BioHarvest’s Botanical Synthesis Technology Platform

BioHarvest Sciences is a pioneer in Botanical Synthesis technology, utilizing a patented platform that enables the production of plant-based compounds without cultivating the actual plants. This proprietary technology distinguishes the company from traditional botanical extraction methods and serves as a key competitive advantage.

The company operates two main business segments: a contract development and manufacturing organization (CDMO) serving clients seeking novel plant-based compounds, and a developer of proprietary nutraceutical and health and wellness products based on its botanical synthesis platform. This dual business model allows BioHarvest to generate revenue from both CDMO services and direct-to-consumer branded products, diversifying its customer base and revenue streams.

CDMO Segment and Client Solutions

Through its CDMO segment, BioHarvest offers development and manufacturing services to customers requiring plant-based molecular solutions. This segment serves pharmaceutical, nutraceutical, and life sciences companies that need botanical-derived compounds but lack in-house production capabilities or capacity using traditional cultivation.

The botanical synthesis platform provides advantages in efficiency, scalability, and consistency compared to conventional methods. By eliminating the need to grow entire plants, the technology reduces lead times, enhances quality control, and lowers environmental impact—factors increasingly valued by customers focused on sustainable and science-driven product development. The August 11 earnings update may reveal details on customer acquisitions, contract wins, or production progress within this segment.

Proprietary Nutraceutical and Wellness Product Development

In addition to CDMO operations, BioHarvest is advancing proprietary nutraceutical and health and wellness products derived from its botanical synthesis technology. This segment enables the company to commercialize branded formulations and capitalize directly on consumer demand for plant-based health solutions without relying solely on third-party contract manufacturing.

This proprietary products segment offers BioHarvest the opportunity to build brand equity, achieve higher margins compared to CDMO services, and establish direct consumer relationships. The strategy aligns with market trends favoring plant-based alternatives in nutraceutical and wellness categories, which have seen sustained interest from consumers and investors alike.

Stock Listings and Shareholder Access

BioHarvest is publicly traded on the NASDAQ under ticker BHST and on the Frankfurt Stock Exchange (FSE) under ticker 8MV0. This dual listing grants the company access to North American and European capital markets, enhancing liquidity and broadening its investor base. The listings reflect its operational presence in Vancouver, British Columbia, and Rehovot, Israel.

The company’s international footprint may be important for investors assessing growth potential and exposure to diverse regulatory and market environments. The August 11 earnings call may address regional performance, operational developments, or strategic initiatives relevant to these markets.

Forward-Looking Statements and Risk Factors

BioHarvest included customary forward-looking statement disclaimers, noting that the information may contain projections based on management’s estimates, beliefs, and expectations. The company cautioned that actual results could differ materially due to various risks and uncertainties.

All forward-looking statements are inherently uncertain and subject to factors beyond the company’s control. Investors are advised not to place undue reliance on these statements. BioHarvest does not intend to update forward-looking disclosures except through regular management reports. Risk factors are detailed in the company’s SEC filings, accessible via the Investor Relations section of the company website or directly at http://www.sec.gov.

Accessing Financial Results and Webcast Replay

The Q2 2026 financial results will be released before market open on August 11, 2026. The live webcast will start at 8:00 AM Eastern Time via the Q4 events platform link provided. Early registration is recommended to avoid connectivity issues.

For those unable to participate live, the webcast recording will be archived and accessible on BioHarvest’s Investor Relations webpage under Events & Presentations for on-demand review.

Investor Considerations for the August 11 Earnings Announcement

The coordinated timing of the earnings release before market open followed by a conference call at 8:00 AM Eastern Time is designed to provide investors and analysts with immediate access to financial data and management commentary within the same trading day. This facilitates informed decision-making regarding the stock.

CEO Rakib’s emphasis on delivering a 2026 strategy and growth update near his 100-day milestone suggests the earnings announcement will carry significance beyond routine quarterly reporting. Investors should consider reviewing the webcast or recording for insights into the company’s strategic direction, operational priorities, and outlook for the remainder of 2026 and beyond.